Genovate Biotechnology Co., Ltd. (4130.TWO)
TWD 20.9
(-1.65%)
TWD 20.9
(-1.65%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 84.78 Million | 1.51 Million | -17.25 Million | 87.07 Million | - |
| Net Income | 30.82 Million | -9 Million | 3.56 Million | 40.75 Million | - |
| Depreciation & Amortization | 36.54 Million | 36.08 Million | 35.81 Million | 35.2 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | 11.7 Million | - | - | - |
| Change in working capital | 17.82 Million | -33.02 Million | -54.8 Million | 16.15 Million | - |
| Other non-cash items | -4.74 Million | -2.44 Million | -1.35 Million | -1.91 Million | - |
| Investing Cash Flow | -78.68 Million | -5.74 Million | 36.89 Million | -15.1 Million | - |
| Investments in PPE | -33.34 Million | -24.01 Million | -18.13 Million | -27.15 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -41.14 Million | -104.9 Million | -25 Million | -65 Million | - |
| Sales/Maturities of investments | - | 121.93 Million | 82.12 Million | 74.45 Million | - |
| Other Investing Activities | -4.19 Million | 1.23 Million | -2.09 Million | 2.6 Million | - |
| Financing Cash Flow | -20.23 Million | -39 Thousand | -44.4 Million | -49.43 Million | - |
| Debt repayment | -111 Thousand | - | - | - | - |
| Dividends payments | -19.14 Million | -37.75 Million | -43.36 Million | -48.21 Million | - |
| Common Stock Repurchased | - | - | - | - | -39 Million |
| Common Stock Issuance | - | 38.88 Million | - | - | - |
| Other Financing Activities | 164 Thousand | 59 Thousand | 183 Thousand | - | -123 Thousand |
| Accounts receivables | 35.2 Million | - | - | - | - |
| Accounts payables | -12.93 Million | - | - | - | - |
| Inventory | 6.21 Million | -5.91 Million | -304 Thousand | -4.01 Million | - |
| Other working capital | -23.6 Million | - | - | - | - |
| Cash at beginning of period | 194.16 Million | 198.44 Million | 223.21 Million | 200.66 Million | - |
| Cash at end of period | 180.03 Million | 194.16 Million | 198.44 Million | 223.21 Million | - |
| Capital Expenditure | -33.34 Million | -24.01 Million | -18.13 Million | -27.15 Million | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -14.13 Million | -4.27 Million | -24.77 Million | 22.54 Million | - |
| Free Cash Flow | 51.43 Million | -22.5 Million | -35.39 Million | 59.92 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 10.72 Million | 20.87 Million | 30.82 Million | -17.21 Million | 17.08 Million | 16.15 Million |
| Depreciation & Amortization | 9.35 Million | 9.12 Million | 36.54 Million | 9.23 Million | 9.23 Million | 9.07 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 17.69 Million | -37.13 Million | 17.82 Million | 19.22 Million | 21.57 Million | -25.03 Million |
| Other non-cash items | -1.57 Million | -1.52 Million | -4.74 Million | -1.37 Million | -1.19 Million | -1.23 Million |
| Investing Cash Flow | -30.35 Million | 13.7 Million | -78.68 Million | -14.93 Million | -29.56 Million | -9.72 Million |
| Investments in PPE | -5.82 Million | -9.4 Million | -33.34 Million | -3.92 Million | -9.75 Million | -10.1 Million |
| Acquisitions | -1.45 Million | - | - | - | - | - |
| Investment purchases | - | -20.95 Million | -41.14 Million | -10.3 Million | -15.94 Million | - |
| Sales/Maturities of investments | -23.54 Million | 38.52 Million | - | - | - | - |
| Other Investing Activities | 471 Thousand | 1.01 Million | -4.19 Million | -705 Thousand | -3.86 Million | 380 Thousand |
| Financing Cash Flow | -307 Thousand | -372 Thousand | -20.23 Million | -220 Thousand | -19.46 Million | -260 Thousand |
| Debt repayment | -307 Thousand | - | - | - | - | - |
| Dividends payments | - | - | -19.14 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -199 Thousand | -12 Thousand | 164 Thousand | 120 Thousand | - | - |
| Accounts receivables | 15.15 Million | - | - | - | - | - |
| Accounts payables | 667 Thousand | - | - | - | - | - |
| Inventory | 3.22 Million | 4.24 Million | 6.21 Million | 1.39 Million | -8.71 Million | 2.26 Million |
| Other working capital | -1.48 Million | - | - | - | - | - |
| Cash at beginning of period | 186.46 Million | 180.03 Million | 194.16 Million | 181.44 Million | 182.59 Million | 195.17 Million |
| Cash at end of period | 192.71 Million | 186.46 Million | 180.03 Million | 180.03 Million | 181.44 Million | 182.59 Million |
| Capital Expenditure | -5.82 Million | -9.4 Million | -33.34 Million | -3.92 Million | -9.75 Million | -10.1 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 6.24 Million | 6.43 Million | -14.13 Million | -1.41 Million | -1.14 Million | -12.58 Million |
| Free Cash Flow | 31.07 Million | -16.3 Million | 51.43 Million | 9.81 Million | 38.12 Million | -12.7 Million |
4147
DLHC
AMIGF
3217
7337
ZKIN